New 5-Day Regimen Approved for Antibiotic - alt.support.sinusitis

Message from discussion New 5-Day Regimen Approved for Antibiotic
Path: g2news2.google.com!news2.google.com!npeer01.iad.highwinds-media.com!news.highwinds-media.com!feed-me.highwinds-media.com!bigfeed3.bellsouth.net!news.bellsouth.net!border2.nntp.dca.giganews.com!nntp.giganews.com!backlog2.nntp.dca.giganews.com!nntp.earthlink.com!news.earthlink.com.POSTED!not-for-mail
NNTP-Posting-Date: Tue, 30 Jun 2009 13:38:12 -0500
Date: Tue, 30 Jun 2009 14:38:13 -0400
From: "Steven L." <sdlit...@earthlink.net>
User-Agent: Thunderbird 2.0.0.22 (Windows/20090605)
MIME-Version: 1.0
Newsgroups: alt.support.sinusitis
Subject: New 5-Day Regimen Approved for Antibiotic
Content-Type: text/plain; charset=ISO-8859-1; format=flowed
Content-Transfer-Encoding: 7bit
Message-ID: <D8Kdnc3GKIoJxtfXnZ2dnUVZ_vOdnZ2d@earthlink.com>
Lines: 32
X-Usenet-Provider: http://www.giganews.com
NNTP-Posting-Host: 68.162.217.190
X-Trace: sv3-vEQl4gOexLWg9lRgkiFw3AmxrmLAPfnCogwnNNB2krAaaCxyXTgd/ZefkiKOmZAjXrq7XyuHYa58gah!skO346sNk3xcjfMmhOTIWHbTfij3EXsbmKJ+XSbtOwPG2cSXZUWeYMt7+uWVSvIKM9dkUKNX74UM!zkrub6eoFDPJqYkwGE1YhbsYXll+6mmOvTA=
X-Abuse-and-DMCA-Info: Please be sure to forward a copy of ALL headers
X-Abuse-and-DMCA-Info: Otherwise we will be unable to process your complaint properly
X-Postfilter: 1.3.39

The U.S. Food and Drug Administration in August approved a new five-day, 
750 mg once daily regimen for Levaquin (levofloxacin) tablets by 
Ortho-McNeil to treat acute bacterial sinusitis. The regimen is the 
first and only short-course fluoroquinolone regimen approved for the 
treatment of acute bacterial sinusitis, according to a company press 
release.

The FDA based the approval on a study that found that this treatment 
regimen is as effective as a traditional regimen of Levaquin 500 mg for 
10 days. The study involved 780 adult outpatients diagnosed with acute 
bacterial sinusitis.

Levaquin is indicated for the treatment of adults with acute bacterial 
sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae and 
Moraxella catarrhalis, the most common causes of acute bacterial sinusitis.

Clinical success rates in the study were seen for 91.4% of patients in 
the five-day group and 88.6% of patients in the 10-day group.

The five-day, 750 mg once daily regimen of Levaquin also is approved for 
adults with community-acquired pneumonia caused by 
penicillin-susceptible Streptococcus pneumoniae (excluding 
drug-resistant strains), Haemophilus influenzae, Haemophilus 
parainfluenzae, Chlamydia pneumoniae or Mycoplasma pneumoniae.

The most common adverse events in clinical trials were nausea and diarrhea.


-- 
Steven L.
Email:  sdlit...@earthlinkNOSPAM.net
Remove the NOSPAM before replying to me.